Navigation Links
Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/14/2008

HAYWARD, Calif., March 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Gary S. Titus, Kosan's Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 28th Annual Health Care Conference in Boston at the Boston Marriott Copley Place on Wednesday, March 19, 2008 at 8:00 a.m. Eastern Time. A live webcast of the presentation can be accessed through http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=KOSN&item_id=17865 88.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Announces Third Quarter 2007 Financial Results
7. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
8. Kosan Announces February 28, 2008 Conference Call and Webcast
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging bio and technology start-ups, is hosting “Celebration Friday” (a ... double event will start with libations and networking at 3:30 p.m. at FITCI’s ...
(Date:4/20/2017)... ... 20, 2017 , ... As part of the Stago ... cases when screening for direct oral anticoagulant. When patients taking direct oral anticoagulants ... parental anticoagulation especially for those at high risk of thrombosis recurrence. ...
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and ... 2 data evaluating galcanezumab for the prevention of migraine ... which will take place April 22-28, 2017, in ... present four abstracts at AAN, including safety and patient ... factors associated with a reduction in monthly migraine headache ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):